



PRESS RELEASE, June 16, 2020

Ann Gidner to become new CEO of SelectImmune Pharma

As announced earlier, the Board of Directors of SelectImmune Pharma has been working for some time to recruit a new CEO. The company is now able to announce that Ann Gidner has been appointed CEO of SelectImmune Pharma AB, commencing August 12, 2020. Ann Gidner has extensive experience of the pharmaceutical industry and life science companies, both internationally and in Sweden.

Ann Gidner has successfully built organizations with an approach characterized by great commitment and focus on growth. She will join the company from the position of Interim CEO of AcuCort AB, while prior to that, she was business area manager for CTS at Inceptua GmbH in Berlin, licensing director at Albumedix A/S (Novozymes Biopharma) in Copenhagen and CEO of pharmaceutical strategy company Monocl AB. Prior to these positions, she gained long experience of global, commercial responsibility in major international CMO (Contract Manufacturing Organization) groups. She built up the business model and achieved a strong increase in sales at Cambrex Corporation, with a base in Sweden and New Jersey, USA, as well as with Saltigo GmbH, with a base in Leverkusen, Germany. Ann Gidner also has board assignments and experience of listing on Nasdaq First North through the company SenzaGen AB.

Jakob Testad, who is Acting CEO of SelectImmune, has been recruited as CEO of Linnane Pharma, SelectImmune Pharma's principal owner. Jakob Testad can therefore continue to drive the development of the Group.

"We are proud to be able to attract such a person as Ann Gidner to SelectImmune and look forward to her extensive experience being applied to the company's rapid development. We

are also grateful for the major progress made during the time that Jakob Testad has been Acting CEO of the Company,” says Catharina Svanborg, Chairman of the Board.

“SelectImmune has a fantastically interesting area of research and overcoming antibiotic resistance is one of the major challenges of our time. I am genuinely looking forward to working with new types of cures together with Catharina Svanborg and the strong research team,” says Ann Gidner.

For more information, please contact:

Catharina Svanborg
Chairman of the Board, SelectImmune Pharma AB
Tel: +46 709 42 65 49
E-mail: catharina.svanborg@med.lu.se

Jakob Testad
Acting CEO, SelectImmune Pharma AB
Tel: +46 708 48 42 10
E-mail: jakob.testad@selectImmune.com

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company’s goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.